Global Pulmonary Embolism Drug Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Pulmonary Embolism Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Pulmonary Embolism Drug Industry Forecast” looks at past sales and reviews total world Pulmonary Embolism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Pulmonary Embolism Drug sales for 2025 through 2031. With Pulmonary Embolism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Embolism Drug industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Embolism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Embolism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pulmonary Embolism Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Embolism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Embolism Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Embolism Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Pulmonary Embolism Drug market?
What factors are driving Pulmonary Embolism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Embolism Drug market opportunities vary by end market size?
How does Pulmonary Embolism Drug break out by Type, by Application?
The global Pulmonary Embolism Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Pulmonary Embolism Drug Industry Forecast” looks at past sales and reviews total world Pulmonary Embolism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Pulmonary Embolism Drug sales for 2025 through 2031. With Pulmonary Embolism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Embolism Drug industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Embolism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Embolism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pulmonary Embolism Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Embolism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Embolism Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Embolism Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- DS-9231
- DS-1040
- TRX-1
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Accu-Break Pharmaceuticals, Inc.
- Dong-A Socio Holdings Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Verseon Corp
What is the 10-year outlook for the global Pulmonary Embolism Drug market?
What factors are driving Pulmonary Embolism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Embolism Drug market opportunities vary by end market size?
How does Pulmonary Embolism Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Embolism Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pulmonary Embolism Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pulmonary Embolism Drug by Country/Region, 2020, 2024 & 2031
2.2 Pulmonary Embolism Drug Segment by Type
2.2.1 DS-9231
2.2.2 DS-1040
2.2.3 TRX-1
2.2.4 Others
2.3 Pulmonary Embolism Drug Sales by Type
2.3.1 Global Pulmonary Embolism Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Pulmonary Embolism Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pulmonary Embolism Drug Sale Price by Type (2020-2025)
2.4 Pulmonary Embolism Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Pulmonary Embolism Drug Sales by Application
2.5.1 Global Pulmonary Embolism Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Pulmonary Embolism Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pulmonary Embolism Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Pulmonary Embolism Drug Breakdown Data by Company
3.1.1 Global Pulmonary Embolism Drug Annual Sales by Company (2020-2025)
3.1.2 Global Pulmonary Embolism Drug Sales Market Share by Company (2020-2025)
3.2 Global Pulmonary Embolism Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Pulmonary Embolism Drug Revenue by Company (2020-2025)
3.2.2 Global Pulmonary Embolism Drug Revenue Market Share by Company (2020-2025)
3.3 Global Pulmonary Embolism Drug Sale Price by Company
3.4 Key Manufacturers Pulmonary Embolism Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Embolism Drug Product Location Distribution
3.4.2 Players Pulmonary Embolism Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PULMONARY EMBOLISM DRUG BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Embolism Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Pulmonary Embolism Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pulmonary Embolism Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pulmonary Embolism Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Pulmonary Embolism Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pulmonary Embolism Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pulmonary Embolism Drug Sales Growth
4.4 APAC Pulmonary Embolism Drug Sales Growth
4.5 Europe Pulmonary Embolism Drug Sales Growth
4.6 Middle East & Africa Pulmonary Embolism Drug Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Embolism Drug Sales by Country
5.1.1 Americas Pulmonary Embolism Drug Sales by Country (2020-2025)
5.1.2 Americas Pulmonary Embolism Drug Revenue by Country (2020-2025)
5.2 Americas Pulmonary Embolism Drug Sales by Type (2020-2025)
5.3 Americas Pulmonary Embolism Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Embolism Drug Sales by Region
6.1.1 APAC Pulmonary Embolism Drug Sales by Region (2020-2025)
6.1.2 APAC Pulmonary Embolism Drug Revenue by Region (2020-2025)
6.2 APAC Pulmonary Embolism Drug Sales by Type (2020-2025)
6.3 APAC Pulmonary Embolism Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Embolism Drug by Country
7.1.1 Europe Pulmonary Embolism Drug Sales by Country (2020-2025)
7.1.2 Europe Pulmonary Embolism Drug Revenue by Country (2020-2025)
7.2 Europe Pulmonary Embolism Drug Sales by Type (2020-2025)
7.3 Europe Pulmonary Embolism Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Embolism Drug by Country
8.1.1 Middle East & Africa Pulmonary Embolism Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pulmonary Embolism Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Pulmonary Embolism Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Pulmonary Embolism Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Embolism Drug
10.3 Manufacturing Process Analysis of Pulmonary Embolism Drug
10.4 Industry Chain Structure of Pulmonary Embolism Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Embolism Drug Distributors
11.3 Pulmonary Embolism Drug Customer
12 WORLD FORECAST REVIEW FOR PULMONARY EMBOLISM DRUG BY GEOGRAPHIC REGION
12.1 Global Pulmonary Embolism Drug Market Size Forecast by Region
12.1.1 Global Pulmonary Embolism Drug Forecast by Region (2026-2031)
12.1.2 Global Pulmonary Embolism Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pulmonary Embolism Drug Forecast by Type (2026-2031)
12.7 Global Pulmonary Embolism Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Accu-Break Pharmaceuticals, Inc.
13.1.1 Accu-Break Pharmaceuticals, Inc. Company Information
13.1.2 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
13.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Accu-Break Pharmaceuticals, Inc. Main Business Overview
13.1.5 Accu-Break Pharmaceuticals, Inc. Latest Developments
13.2 Dong-A Socio Holdings Co. Ltd.
13.2.1 Dong-A Socio Holdings Co. Ltd. Company Information
13.2.2 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
13.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Dong-A Socio Holdings Co. Ltd. Main Business Overview
13.2.5 Dong-A Socio Holdings Co. Ltd. Latest Developments
13.3 F. Hoffmann-La Roche Ltd.
13.3.1 F. Hoffmann-La Roche Ltd. Company Information
13.3.2 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
13.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.3.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.4 Genentech, Inc.
13.4.1 Genentech, Inc. Company Information
13.4.2 Genentech, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
13.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Genentech, Inc. Main Business Overview
13.4.5 Genentech, Inc. Latest Developments
13.5 Verseon Corp
13.5.1 Verseon Corp Company Information
13.5.2 Verseon Corp Pulmonary Embolism Drug Product Portfolios and Specifications
13.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Verseon Corp Main Business Overview
13.5.5 Verseon Corp Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Pulmonary Embolism Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Pulmonary Embolism Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of DS-9231
Table 4. Major Players of DS-1040
Table 5. Major Players ofTRX-1
Table 6. Major Players of Others
Table 7. Global Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 8. Global Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Table 9. Global Pulmonary Embolism Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Pulmonary Embolism Drug Revenue Market Share byType (2020-2025)
Table 11. Global Pulmonary Embolism Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 12. Global Pulmonary Embolism Drug Sale by Application (2020-2025) & (K Pcs)
Table 13. Global Pulmonary Embolism Drug Sale Market Share by Application (2020-2025)
Table 14. Global Pulmonary Embolism Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Pulmonary Embolism Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Pulmonary Embolism Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 17. Global Pulmonary Embolism Drug Sales by Company (2020-2025) & (K Pcs)
Table 18. Global Pulmonary Embolism Drug Sales Market Share by Company (2020-2025)
Table 19. Global Pulmonary Embolism Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Pulmonary Embolism Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Pulmonary Embolism Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 22. Key Manufacturers Pulmonary Embolism Drug Producing Area Distribution and Sales Area
Table 23. Players Pulmonary Embolism Drug Products Offered
Table 24. Pulmonary Embolism Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Pulmonary Embolism Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 28. Global Pulmonary Embolism Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Pulmonary Embolism Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Pulmonary Embolism Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Pulmonary Embolism Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 32. Global Pulmonary Embolism Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Pulmonary Embolism Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Pulmonary Embolism Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 36. Americas Pulmonary Embolism Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Pulmonary Embolism Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 39. Americas Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 40. APAC Pulmonary Embolism Drug Sales by Region (2020-2025) & (K Pcs)
Table 41. APAC Pulmonary Embolism Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Pulmonary Embolism Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 44. APAC Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 45. Europe Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 46. Europe Pulmonary Embolism Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 48. Europe Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Middle East & Africa Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Key Market Drivers & Growth Opportunities of Pulmonary Embolism Drug
Table 54. Key Market Challenges & Risks of Pulmonary Embolism Drug
Table 55. Key IndustryTrends of Pulmonary Embolism Drug
Table 56. Pulmonary Embolism Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Pulmonary Embolism Drug Distributors List
Table 59. Pulmonary Embolism Drug Customer List
Table 60. Global Pulmonary Embolism Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 61. Global Pulmonary Embolism Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 63. Americas Pulmonary Embolism Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Pulmonary Embolism Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. APAC Pulmonary Embolism Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Europe Pulmonary Embolism Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Middle East & Africa Pulmonary Embolism Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Pulmonary Embolism Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 71. Global Pulmonary Embolism Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Pulmonary Embolism Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 73. Global Pulmonary Embolism Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Accu-Break Pharmaceuticals, Inc. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 76. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 77. Accu-Break Pharmaceuticals, Inc. Main Business
Table 78. Accu-Break Pharmaceuticals, Inc. Latest Developments
Table 79. Dong-A Socio Holdings Co. Ltd. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 81. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 82. Dong-A Socio Holdings Co. Ltd. Main Business
Table 83. Dong-A Socio Holdings Co. Ltd. Latest Developments
Table 84.F. Hoffmann-La Roche Ltd. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 85.F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 86.F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 87.F. Hoffmann-La Roche Ltd. Main Business
Table 88.F. Hoffmann-La Roche Ltd. Latest Developments
Table 89. Genentech, Inc. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Genentech, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 91. Genentech, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 92. Genentech, Inc. Main Business
Table 93. Genentech, Inc. Latest Developments
Table 94. Verseon Corp Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Verseon Corp Pulmonary Embolism Drug Product Portfolios and Specifications
Table 96. Verseon Corp Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 97. Verseon Corp Main Business
Table 98. Verseon Corp Latest Developments
LIST OFFIGURES
Figure 1. Picture of Pulmonary Embolism Drug
Figure 2. Pulmonary Embolism Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Embolism Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Pulmonary Embolism Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Pulmonary Embolism Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Pulmonary Embolism Drug Sales Market Share by Country/Region (2024)
Figure 10. Pulmonary Embolism Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of DS-9231
Figure 12. Product Picture of DS-1040
Figure 13. Product Picture ofTRX-1
Figure 14. Product Picture of Others
Figure 15. Global Pulmonary Embolism Drug Sales Market Share byType in 2025
Figure 16. Global Pulmonary Embolism Drug Revenue Market Share byType (2020-2025)
Figure 17. Pulmonary Embolism Drug Consumed in Hospital
Figure 18. Global Pulmonary Embolism Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 19. Pulmonary Embolism Drug Consumed in Clinic
Figure 20. Global Pulmonary Embolism Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 21. Pulmonary Embolism Drug Consumed in Others
Figure 22. Global Pulmonary Embolism Drug Market: Others (2020-2025) & (K Pcs)
Figure 23. Global Pulmonary Embolism Drug Sale Market Share by Application (2024)
Figure 24. Global Pulmonary Embolism Drug Revenue Market Share by Application in 2025
Figure 25. Pulmonary Embolism Drug Sales by Company in 2025 (K Pcs)
Figure 26. Global Pulmonary Embolism Drug Sales Market Share by Company in 2025
Figure 27. Pulmonary Embolism Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Pulmonary Embolism Drug Revenue Market Share by Company in 2025
Figure 29. Global Pulmonary Embolism Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Pulmonary Embolism Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 32. Americas Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 34. APAC Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 36. Europe Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 38. Middle East & Africa Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Pulmonary Embolism Drug Sales Market Share by Country in 2025
Figure 40. Americas Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Pulmonary Embolism Drug Sales Market Share by Region in 2025
Figure 48. APAC Pulmonary Embolism Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 51. China Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Pulmonary Embolism Drug Sales Market Share by Country in 2025
Figure 59. Europe Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Pulmonary Embolism Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Pulmonary Embolism Drug in 2025
Figure 76. Manufacturing Process Analysis of Pulmonary Embolism Drug
Figure 77. Industry Chain Structure of Pulmonary Embolism Drug
Figure 78. Channels of Distribution
Figure 79. Global Pulmonary Embolism Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Pulmonary Embolism Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Pulmonary Embolism Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Pulmonary Embolism Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Pulmonary Embolism Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Pulmonary Embolism Drug Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Embolism Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pulmonary Embolism Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pulmonary Embolism Drug by Country/Region, 2020, 2024 & 2031
2.2 Pulmonary Embolism Drug Segment by Type
2.2.1 DS-9231
2.2.2 DS-1040
2.2.3 TRX-1
2.2.4 Others
2.3 Pulmonary Embolism Drug Sales by Type
2.3.1 Global Pulmonary Embolism Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Pulmonary Embolism Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pulmonary Embolism Drug Sale Price by Type (2020-2025)
2.4 Pulmonary Embolism Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Pulmonary Embolism Drug Sales by Application
2.5.1 Global Pulmonary Embolism Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Pulmonary Embolism Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pulmonary Embolism Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Pulmonary Embolism Drug Breakdown Data by Company
3.1.1 Global Pulmonary Embolism Drug Annual Sales by Company (2020-2025)
3.1.2 Global Pulmonary Embolism Drug Sales Market Share by Company (2020-2025)
3.2 Global Pulmonary Embolism Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Pulmonary Embolism Drug Revenue by Company (2020-2025)
3.2.2 Global Pulmonary Embolism Drug Revenue Market Share by Company (2020-2025)
3.3 Global Pulmonary Embolism Drug Sale Price by Company
3.4 Key Manufacturers Pulmonary Embolism Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Embolism Drug Product Location Distribution
3.4.2 Players Pulmonary Embolism Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PULMONARY EMBOLISM DRUG BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Embolism Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Pulmonary Embolism Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pulmonary Embolism Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pulmonary Embolism Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Pulmonary Embolism Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pulmonary Embolism Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pulmonary Embolism Drug Sales Growth
4.4 APAC Pulmonary Embolism Drug Sales Growth
4.5 Europe Pulmonary Embolism Drug Sales Growth
4.6 Middle East & Africa Pulmonary Embolism Drug Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Embolism Drug Sales by Country
5.1.1 Americas Pulmonary Embolism Drug Sales by Country (2020-2025)
5.1.2 Americas Pulmonary Embolism Drug Revenue by Country (2020-2025)
5.2 Americas Pulmonary Embolism Drug Sales by Type (2020-2025)
5.3 Americas Pulmonary Embolism Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Embolism Drug Sales by Region
6.1.1 APAC Pulmonary Embolism Drug Sales by Region (2020-2025)
6.1.2 APAC Pulmonary Embolism Drug Revenue by Region (2020-2025)
6.2 APAC Pulmonary Embolism Drug Sales by Type (2020-2025)
6.3 APAC Pulmonary Embolism Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Embolism Drug by Country
7.1.1 Europe Pulmonary Embolism Drug Sales by Country (2020-2025)
7.1.2 Europe Pulmonary Embolism Drug Revenue by Country (2020-2025)
7.2 Europe Pulmonary Embolism Drug Sales by Type (2020-2025)
7.3 Europe Pulmonary Embolism Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Embolism Drug by Country
8.1.1 Middle East & Africa Pulmonary Embolism Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pulmonary Embolism Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Pulmonary Embolism Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Pulmonary Embolism Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Embolism Drug
10.3 Manufacturing Process Analysis of Pulmonary Embolism Drug
10.4 Industry Chain Structure of Pulmonary Embolism Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Embolism Drug Distributors
11.3 Pulmonary Embolism Drug Customer
12 WORLD FORECAST REVIEW FOR PULMONARY EMBOLISM DRUG BY GEOGRAPHIC REGION
12.1 Global Pulmonary Embolism Drug Market Size Forecast by Region
12.1.1 Global Pulmonary Embolism Drug Forecast by Region (2026-2031)
12.1.2 Global Pulmonary Embolism Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pulmonary Embolism Drug Forecast by Type (2026-2031)
12.7 Global Pulmonary Embolism Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Accu-Break Pharmaceuticals, Inc.
13.1.1 Accu-Break Pharmaceuticals, Inc. Company Information
13.1.2 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
13.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Accu-Break Pharmaceuticals, Inc. Main Business Overview
13.1.5 Accu-Break Pharmaceuticals, Inc. Latest Developments
13.2 Dong-A Socio Holdings Co. Ltd.
13.2.1 Dong-A Socio Holdings Co. Ltd. Company Information
13.2.2 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
13.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Dong-A Socio Holdings Co. Ltd. Main Business Overview
13.2.5 Dong-A Socio Holdings Co. Ltd. Latest Developments
13.3 F. Hoffmann-La Roche Ltd.
13.3.1 F. Hoffmann-La Roche Ltd. Company Information
13.3.2 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
13.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.3.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.4 Genentech, Inc.
13.4.1 Genentech, Inc. Company Information
13.4.2 Genentech, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
13.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Genentech, Inc. Main Business Overview
13.4.5 Genentech, Inc. Latest Developments
13.5 Verseon Corp
13.5.1 Verseon Corp Company Information
13.5.2 Verseon Corp Pulmonary Embolism Drug Product Portfolios and Specifications
13.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Verseon Corp Main Business Overview
13.5.5 Verseon Corp Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Pulmonary Embolism Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Pulmonary Embolism Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of DS-9231
Table 4. Major Players of DS-1040
Table 5. Major Players ofTRX-1
Table 6. Major Players of Others
Table 7. Global Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 8. Global Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Table 9. Global Pulmonary Embolism Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Pulmonary Embolism Drug Revenue Market Share byType (2020-2025)
Table 11. Global Pulmonary Embolism Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 12. Global Pulmonary Embolism Drug Sale by Application (2020-2025) & (K Pcs)
Table 13. Global Pulmonary Embolism Drug Sale Market Share by Application (2020-2025)
Table 14. Global Pulmonary Embolism Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Pulmonary Embolism Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Pulmonary Embolism Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 17. Global Pulmonary Embolism Drug Sales by Company (2020-2025) & (K Pcs)
Table 18. Global Pulmonary Embolism Drug Sales Market Share by Company (2020-2025)
Table 19. Global Pulmonary Embolism Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Pulmonary Embolism Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Pulmonary Embolism Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 22. Key Manufacturers Pulmonary Embolism Drug Producing Area Distribution and Sales Area
Table 23. Players Pulmonary Embolism Drug Products Offered
Table 24. Pulmonary Embolism Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Pulmonary Embolism Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 28. Global Pulmonary Embolism Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Pulmonary Embolism Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Pulmonary Embolism Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Pulmonary Embolism Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 32. Global Pulmonary Embolism Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Pulmonary Embolism Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Pulmonary Embolism Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 36. Americas Pulmonary Embolism Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Pulmonary Embolism Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 39. Americas Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 40. APAC Pulmonary Embolism Drug Sales by Region (2020-2025) & (K Pcs)
Table 41. APAC Pulmonary Embolism Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Pulmonary Embolism Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 44. APAC Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 45. Europe Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 46. Europe Pulmonary Embolism Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 48. Europe Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Middle East & Africa Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Pulmonary Embolism Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Pulmonary Embolism Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Key Market Drivers & Growth Opportunities of Pulmonary Embolism Drug
Table 54. Key Market Challenges & Risks of Pulmonary Embolism Drug
Table 55. Key IndustryTrends of Pulmonary Embolism Drug
Table 56. Pulmonary Embolism Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Pulmonary Embolism Drug Distributors List
Table 59. Pulmonary Embolism Drug Customer List
Table 60. Global Pulmonary Embolism Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 61. Global Pulmonary Embolism Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 63. Americas Pulmonary Embolism Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Pulmonary Embolism Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. APAC Pulmonary Embolism Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Europe Pulmonary Embolism Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Pulmonary Embolism Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Middle East & Africa Pulmonary Embolism Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Pulmonary Embolism Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 71. Global Pulmonary Embolism Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Pulmonary Embolism Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 73. Global Pulmonary Embolism Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Accu-Break Pharmaceuticals, Inc. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 76. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 77. Accu-Break Pharmaceuticals, Inc. Main Business
Table 78. Accu-Break Pharmaceuticals, Inc. Latest Developments
Table 79. Dong-A Socio Holdings Co. Ltd. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 81. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 82. Dong-A Socio Holdings Co. Ltd. Main Business
Table 83. Dong-A Socio Holdings Co. Ltd. Latest Developments
Table 84.F. Hoffmann-La Roche Ltd. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 85.F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 86.F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 87.F. Hoffmann-La Roche Ltd. Main Business
Table 88.F. Hoffmann-La Roche Ltd. Latest Developments
Table 89. Genentech, Inc. Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Genentech, Inc. Pulmonary Embolism Drug Product Portfolios and Specifications
Table 91. Genentech, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 92. Genentech, Inc. Main Business
Table 93. Genentech, Inc. Latest Developments
Table 94. Verseon Corp Basic Information, Pulmonary Embolism Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Verseon Corp Pulmonary Embolism Drug Product Portfolios and Specifications
Table 96. Verseon Corp Pulmonary Embolism Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 97. Verseon Corp Main Business
Table 98. Verseon Corp Latest Developments
LIST OFFIGURES
Figure 1. Picture of Pulmonary Embolism Drug
Figure 2. Pulmonary Embolism Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Embolism Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Pulmonary Embolism Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Pulmonary Embolism Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Pulmonary Embolism Drug Sales Market Share by Country/Region (2024)
Figure 10. Pulmonary Embolism Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of DS-9231
Figure 12. Product Picture of DS-1040
Figure 13. Product Picture ofTRX-1
Figure 14. Product Picture of Others
Figure 15. Global Pulmonary Embolism Drug Sales Market Share byType in 2025
Figure 16. Global Pulmonary Embolism Drug Revenue Market Share byType (2020-2025)
Figure 17. Pulmonary Embolism Drug Consumed in Hospital
Figure 18. Global Pulmonary Embolism Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 19. Pulmonary Embolism Drug Consumed in Clinic
Figure 20. Global Pulmonary Embolism Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 21. Pulmonary Embolism Drug Consumed in Others
Figure 22. Global Pulmonary Embolism Drug Market: Others (2020-2025) & (K Pcs)
Figure 23. Global Pulmonary Embolism Drug Sale Market Share by Application (2024)
Figure 24. Global Pulmonary Embolism Drug Revenue Market Share by Application in 2025
Figure 25. Pulmonary Embolism Drug Sales by Company in 2025 (K Pcs)
Figure 26. Global Pulmonary Embolism Drug Sales Market Share by Company in 2025
Figure 27. Pulmonary Embolism Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Pulmonary Embolism Drug Revenue Market Share by Company in 2025
Figure 29. Global Pulmonary Embolism Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Pulmonary Embolism Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 32. Americas Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 34. APAC Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 36. Europe Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Pulmonary Embolism Drug Sales 2020-2025 (K Pcs)
Figure 38. Middle East & Africa Pulmonary Embolism Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Pulmonary Embolism Drug Sales Market Share by Country in 2025
Figure 40. Americas Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Pulmonary Embolism Drug Sales Market Share by Region in 2025
Figure 48. APAC Pulmonary Embolism Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 51. China Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Pulmonary Embolism Drug Sales Market Share by Country in 2025
Figure 59. Europe Pulmonary Embolism Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Pulmonary Embolism Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Pulmonary Embolism Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Pulmonary Embolism Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Pulmonary Embolism Drug in 2025
Figure 76. Manufacturing Process Analysis of Pulmonary Embolism Drug
Figure 77. Industry Chain Structure of Pulmonary Embolism Drug
Figure 78. Channels of Distribution
Figure 79. Global Pulmonary Embolism Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Pulmonary Embolism Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Pulmonary Embolism Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Pulmonary Embolism Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Pulmonary Embolism Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Pulmonary Embolism Drug Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Customer Review Marketing Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
June 2024
100 pages
Global Cloud Encryption Gateways Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
January 2025
100 pages
Global Original Design Manufacturer Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
March 2023
122 pages
Global Digital Vinyl Systems (DVS) Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
87 pages
Global LVDT Linear Position Sensors Market Growth 2025-2031
US$ 3,660.00
November 2025
111 pages
